“Efficacy and Safety of Ruxolitinib Cream by Anatomic Region in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s453. doi:10.25251/skin.8.supp.453.